Revenue
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Viking Therapeutics, Inc. (VKTX)
Price$30.11Cached quote
Net income
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
No reported data
Total cash / debt
CashTotal debt
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Research & development | $345.0M | $101.6M | $63.8M | $54.2M | $45.0M | $31.9M | $23.6M | $19.0M | $13.7M | $9.0M | $7.0M | $22.2M |
| Operating expenses | $393.3M | $150.9M | $100.8M | $70.4M | $55.7M | $42.7M | $32.7M | $26.2M | $19.1M | $13.8M | $12.0M | $23.5M |
| Operating income | −$393.3M | −$150.9M | −$100.8M | −$70.4M | −$55.7M | −$42.7M | −$32.7M | −$26.2M | −$19.1M | −$13.8M | −$12.0M | −$23.5M |
| EBITDA | −$392.9M | −$150.6M | −$100.5M | −$70.1M | — | — | — | — | — | — | — | — |
| Net income | −$359.6M | −$110.0M | −$85.9M | −$68.9M | −$55.0M | −$39.5M | −$25.8M | −$22.1M | −$20.6M | −$14.7M | −$23.4M | −$21.9M |
| Basic EPSper basic share | -$3.19 | -$1.01 | -$0.91 | -$0.90 | -$0.71 | -$0.54 | -$0.36 | -$0.38 | -$0.79 | -$0.90 | -$3.68 | -$5.23 |
| Diluted EPSper diluted share | -$3.19 | -$1.01 | -$0.91 | -$0.90 | -$0.71 | -$0.54 | -$0.36 | -$0.38 | -$0.79 | -$0.90 | -$3.68 | -$5.23 |
Owners
Reported shareholders
5.43%of listed shares
FMR LLC6.34M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
FMR LLC | 5.43%6.34M shares |
BlackRock, Inc. | 5.31%6.19M shares |
STATE STREET CORP | 4.81%5.61M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 4.33%5.05M shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 3.84%4.48M shares |
TWO SIGMA INVESTMENTS, LP | 3.38%3.94M shares |
MORGAN STANLEY | 2.99%3.49M shares |
Lian Brian | ≈2.14%2.5M shares |
AMERIPRISE FINANCIAL INC | 1.85%2.16M shares |
GEODE CAPITAL MANAGEMENT, LLC | 1.80%2.1M shares |
AMERICAN CENTURY COMPANIES INC | 1.56%1.82M shares |
D. E. Shaw & Co., Inc. | 1.38%1.61M shares |
BNP PARIBAS FINANCIAL MARKETS | 0.84%981.7K shares |
CITADEL ADVISORS LLC | 0.82%951.52K shares |
GOLDMAN SACHS GROUP INC | 0.81%942.84K shares |
UBS Group AG | 0.80%936.06K shares |
JPMORGAN CHASE & CO | 0.78%915.19K shares |
JANE STREET GROUP, LLC | 0.77%899.56K shares |
SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.70%816.37K shares |
RAYMOND JAMES FINANCIAL INC | 0.68%794.66K shares |
Percentages use 116.65M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Mar 10, 2026Form 4 | Aubuchon Neil WilliamChief Commercial Officer | BuyCommon Stock, par value $0.00001 per share | 4.5K | $33.50 | $149.9K | 4.5K |
| Jan 5, 2026Form 4 | ZANTE GREGChief Financial Officer | SellCommon Stock, par value $0.00001 per share | 1.5K | $32.09 | $48.1K | 189.9K |
| Jan 5, 2026Form 4 | ZANTE GREGChief Financial Officer | SellCommon Stock, par value $0.00001 per share | 10.3K | $34.24 | $352.7K | 191.4K |
| Jan 5, 2026Form 4 | ZANTE GREGChief Financial Officer | SellCommon Stock, par value $0.00001 per share | 13.9K | $33.38 | $464.0K | 201.7K |
| Jan 5, 2026Form 4 | ZANTE GREGChief Financial Officer | SellCommon Stock, par value $0.00001 per share | 32.0K | $32.30 | $1.03M | 215.6K |